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Introduction
The discovery of antibiotics and their subsequent intro-
duction into clinical medicine has been one of the main 
prerequisites for our current – modern day – healthcare 
to develop (Gaynes 2017). Previously lethal infections 
have become manageable, the life expectancy of people 
worldwide has changed drastically and novel medical 
interventions (e.g., cancer chemotherapy, invasive sur-
gery, organ transplantation, and neonatology) were made 
possible (Laxminarayan et al. 2013). Bacterial pathogens 
have also reacted to the use of these agents and developed 
various resistance mechanisms to avoid their lethal effects 
(Nikaido 2009). The development of resistant isolates 
was to be expected by the laws of Darwinian evolution; 
however, the misuse and overuse of these agents have 
catalyzed this process to become a severe health problem 
in the span of only a few decades (Chang et al. 2015). 
Currently, the emergence of multidrug-resistant (MDR) 
bacteria is a global public health issue, which severely 
hinders clinicians in providing patients with adequate 
antimicrobial treatment regimens (Gajdács and Albericio 
2019; Munita and Arias 2016). Several national and global 
public health authorities have published reports and esti-
mates on the global impact of antibiotic resistance (World 
Health Organization 2014). The grimmest predictions 
may be found in the O’Neill report (from the National 
Health Service of the United Kingdom), projecting 10 
million deaths per year by 2050 and 100 billion USD 
worth of economic burden (O’Neill 2014). Rice et al. have 
defined the „ESKAPE” bacteria (including E: Enterococcus 
faecium, S: Staphylococcus aureus, K: Klebsiella pneumoniae, 
A: Acinetobacter baumannii, P: Pseudomonas aeruginosa, E: 
Enterobacter spp., or recently Enterobacteriaceae) as the most 
concerning from the standpoint of clinical impact, both 
mortality-wise and economically (Rice 2010). 
The issue of antibiotic resistance in the 21st century is 
a three-sided problem: i) on one hand, the emerge of drug-
resistant mutants against newly developed antibiotics is an 
inevitable evolutionary process (which is common against 
any kind of noxious agents), ii) while the non-prudent use 
of antibiotics (e.g., for viral infections or other inappro-
priate indications) only exacerbates this process; iii) the 
costs of clinical research and the development of novel 
antibiotics – coupled with the relatively modest returns 
on investment from these drugs – lead to a shift in the 
interest of pharmaceutical companies to instead develop 
drugs for chronic (i.e. more „profitable”) illnesses; this has 
resulted in a „discovery void”, with very limited amount 
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of novel agents receiving marketing authorization since 
the 2000s (Gajdács 2019; Gajdács et al. 2020). In fact, no 
new broad-spectrum antibiotics were developed since the 
introduction of the fluoroquinolones in the 1980s (Darrow 
and Kesselheim 2014). Without new agents, researchers 
have investigated alternative strategies to combat bacte-
rial pathogens more effectively (Rios et al. 2016). One of 
the proposed strategies is combination therapy: while 
the use of two or more existing antibiotics simultane-
ously in clinical situations is a controversial topic (with 
very few verified indications), however, the inclusion of 
non-antibiotic adjuvants seems to be a promising strat-
egy (Ahmed et al. 2014; Tangdén 2014; Szerencsés et al. 
2019). These adjuvants include enzyme inhibitors (e.g., 
clavulanic acid, a β-lactamase inhibitor), efflux pump 
inhibitors, modulators of bacterial membrane potential, 
membrane permeabilizers, inhibitors of bacterial cell-
cell communication (quorum sensing) and monoclonal 
antibodies (Wright 2016; Kealey et al. 2017; Drawz and 
Bonomo 2010). However, it must be noted that most of 
these molecules did not receive clinical approval due to 
their toxicity in vivo (Tegos et al. 2011). Recently, the ad-
juvant properties of existing pharmaceutical compounds 
have received substantial attention. This strategy is termed 
„drug repurposing” (or drug re-profiling), during which 
new pharmacological uses are identified for drugs already 
approved, outside of their original indications (Pushpakom 
et al. 2019). As the physicochemical, pharmacokinetic and 
toxicological profile of these compounds have already 
been established, the initial stages of the drug authoriza-
tion process (Phase I–II clinical trials) may be avoided, 
leading to substantial monetary benefits for the pharma-
ceutical companies; if this new indication of the tested 
compound is appropriate, pharmaceutical companies may 
once again expect financial returns for their investments 
(Miró-Canturri et al. 2019; Paul et al. 2010; Pushpakom 
et al. 2019; Soo et al. 2017). Drug re-profiling is also 
an emerging strategy in antimicrobial chemotherapy: 
some of these compounds have antibacterial properties 
themselves, while others have secondary mechanisms 
of action (some of which are unknown as of now). These 
mechanisms may include: bacteriostatic properties, inhibi-
tion of bacterial cell-cell communication, modulation of 
virulence factor-expression, biofilm-inhibition and so on 
(Miró-Canturri et al. 2019; Paul et al. 2010; Pushpakom et 
al. 2019; Soo et al. 2017; Yang et al. 2009) However, there 
are still significant gaps in the knowledge in the field of 
drug repurposing for antimicrobial purposes.
The aim of our present study was to assess the ad-
juvant properties of several existing and widely-used 
pharmacological agents against bacteria in combination 
with reference antibiotics, in an in vitro study.
Materials and methods
Culture media
The following culture media were used during our ex-
periments: cation-adjusted Mueller-Hinton broth (Bio-
Rad, Hercules, CA, USA), Luria–Bertani broth (Bio-Rad, 
Hercules, CA, USA), 5% sheep blood agar (bioMérieux, 
Marcy-l’Étoile, France) and eosine-methylene blue agar 
(bioMérieux, Marcy-l’Étoile, France). 
Bacterial strains
Staphylococcus aureus ATCC 25923 and S. epidermidis ATCC 
12228 were used as representative Gram-positive strains, 
while E. coli ATCC 25922 and K. pneumoniae ATCC 700603 
were selected as representative Gram-negative strains for 
our experiments. For shorter time periods (<1 month), 
the bacterial strains were maintained on blood agar and 
eosine-methylene blue agar plates (for Gram-negatives) 
with continuous passage. For longer periods, the strains 
were kept in a -80 °C freezer, in a 1:4 mixture of 85% 
glycerol and liquid Luria-Bertani medium.
Antibiotics and non-antibiotic compounds
Ciprofloxacin and gentamicin (Sigma-Aldrich, St. Louis, 
MI, USA; will be listed as SA in the subsequent text) were 
selected as antibiotic controls for our studies. Twenty (n 
= 20) pharmacological agents, encompassing drug with 
different chemical structures and mechanisms of action 
were tested during our experiments: acetaminophen 
(SA), amantadine (SA), acyclovir (Teva Pharmaceuticals, 
Petah Tikva, Israel; will be listed as TPh in the subsequent 
text), atorvastatin (SA), azelastine (SA), celecoxib (Pfizer 
Hungary, Budapest, Hungary), cetirizine (SA), clotrima-
zole (TPh), diclofenac-epolamine (SA), enalapril-maleate 
(SA), ivermectin (SA), lidocaine (SA), mebendazole (SA), 
metformin (SA), metoprolol-succinate (SA), prazozine 
(SA), sitagliptine (SA), terbinafine (GlaxoSmithKline, 
Brentford, UK), valsartan (SA) and xylomethazoline 
(SA). The compounds were chosen on the basis of being 
available as over-the-counter (OTC) medication or being 
frequently prescribed for common chronic conditions 
as hypertension or diabetes mellitus. Pharmaceutical 
compounds were dissolved in phosphate-buffered saline 
(PBS), except for atorvastatin, which was dissolved in 
dimethyl sulfoxide (DMSO). All solutions were prepared 
on the day of the assay. The concentration of DMSO was 
below 1 V/V% in all experiments. 
Antibacterial activity of non-antibiotic compounds, MIC 
determination
The minimum inhibitory concentrations (MICs) of the 
tested compounds were determined using the standard 
broth microdilution method, based on the recommenda-
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tions of the Clinical and Laboratory Standards Institute 
(CLSI; M07-A10). The experiments were performed in 96-
well polystyrene microtiter plates, using cation-adjusted 
Mueller–Hinton broth. The tested concentrations of the 
compounds were ranging between 1.95-250 µg/mL, the 
two-fold serial dilutions of the tested compounds were 
made starting in the third row of the microtiter plates. 
During the experiments with S. aureus ATCC 25922 and 
S. epidermidis ATCC 12228, the Mueller-Hinton broth was 
supplemented by 2% NaCl, as based on CLSI protocols. 
The plates were incubated at 37 °C in an air thermostat. 
The MIC values of the tested compounds were recorded 
after 16-18 h of incubation; the interpretation of the 
results was performed visually. All experiments were 
performed in triplicate.
MIC reduction assay 
To ascertain the effect of the tested compounds on the 
MICs of standard antibiotics (i.e. ciprofloxacin and gen-
tamicin), a MIC reduction assay was performed (Sarker et 
al. 2007). The assay was performed in a 96-well microtiter 
plate, using cation-adjusted Mueller-Hinton broth. The 
setup of the plates was the following: in rows A-D of 
the plate, serial dilutions were made for the reference 
antibiotic, in rows E-H the same serial dilutions were 
performed for the reference antibiotic with the addition of 
the non-antibiotic compounds in a constant concentration 
as adjuvants (MIC/4 in cases where MIC was ≤ 250 µg/
mL and 125 µg/mL where MICs were higher than 250 
µg/mL) in all the wells, except for medium control and 
cell control wells (Sarker et al. 2007). The inoculation of 
the plates and the incubation was performed according 
to a standard broth microdilution method, described 
previously. The modified MICs (compared to the MICs 
of the antibiotics alone) were determined visually, as the 
concentration, where no visible growth of bacteria could 
be observed. All experiments were carried out in triplicate.
Results 
Antibacterial activity of pharmaceutical compounds
The MICs observed for the non-antibiotic pharmaceu-
tical compounds is presented in Table 1. Eight tested 
compounds (namely atorvastatin, celecoxib, clotrimazole, 
diclofenac-epolamine, ivermectin, lidocaine, mebendazole 
and terbinafine) showed antibacterial activities in the 
tested concentration range, while compounds with MICs 
>250 µg/mL were not considered to be active.
MIC reduction assays
The results of the MIC reduction assays for Gram-positive 
Minimal inhibitory concentrations (µg/mL)
Compounds S. aureus ATCC 25923 S. epidermidis ATCC 12228 E. coli ATCC 25922 K. pneumoniae ATCC 700603
Acetaminophen >250 >250 >250 >250
Amantadine >250 >250 >250 >250
Acyclovir >250 >250 >250 >250
Atorvastatin 125 125 250 >250
Azelastine >250 >250 >250 >250
Celecoxib 15.6 31.2 >250 >250
Cetirizine >250 >250 >250 >250
Clotrimazole 125 62.5 >250 >250
Diclofenac-epolamine 250 250 >250 >250
Enalapril-maleate >250 >250 >250 >250
Ivermectin 31.2 125 >250 >250
Lidocaine 250 250 250 250
Mebendazole 62.5 125 62.5 250
Metformin >250 >250 >250 >250
Metoprolol-succinate >250 >250 >250 >250
Prazozine >250 >250 >250 >250
Sitagliptine >250 >250 >250 >250
Terbinafine 250 125 >250 >250
Valsartan >250 >250 >250 >250
Xylomethazoline >250 >250 >250 >250
Table 1 Minimum inhibitory concentrations (MICs) of the tested pharmaceutical compounds on reference bacterial strains.
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bacteria are presented in Table 2., while results for Gram-
negative bacteria are shown in Table 3. Overall, the tested 
non-antibiotics were the most potent adjuvants against 
Gram-positive bacteria and they enhanced the antibacte-
rial activity (i.e. they reduced the MICs) or ciprofloxacin 
to the highest extent (reducing the MICs 50-93.25% or 
2-5-fold), while having modest effects on Gram-negative 
bacteria (E. coli and K. pneumoniae) and on the MICs of 
gentamicin. Interestingly, azelastine and valsartan on 
Gram-positive bacteria, while cetirizine, enalapril, val-
sartan and xylomethazoline on Gram-negative bacteria 
had MIC-reducing effects, without having any intrinsic 
antibacterial properties themselves (see Table 1.).
Discussion
Infections caused by MDR bacteria are associated with 
an increased mortality rate and decreased quality of life 
in the affected patients worldwide (Falagas et al. 2008). 
Since the 2000s, the development of novel antibiotics has 
been shown to keep up with the development in the levels 
of bacterial resistance (Falagas et al. 2008). Combination 
therapy with non-antibiotic compounds may provide a 
straightforward, attractive and financially reasonable drug 
development avenue (Medina and Pieper 2016; Lyddiard 
et al. 2016; Spellberg 2014). Several reports have been 
published in the literature on the antibacterial properties 
of non-antibiotic drugs; however, the systematic screening 
of drugs for such purposes have not yet been performed 
(Kruszewska et al. 2002; Lagadinou et al. 2020). Doxo-
rubicin and bleomycin are antitumor agents (frequently 
termed as “anticancer antibiotics”) show antibacterial 
properties on a variety of bacterial strains: the proposed 
mechanism of action is related to their intercalation into 
bacterial DNA (similar to the mechanism of the fluoro-
quinolones) and the generation of oxidative free radicals 
in the presence of Fe2+-ions (which are indispensable for 
the biochemical pathways of bacteria) (Kruszewska et 
al. 2002; Lagadinou et al. 2020; Soo et al. 2017). Several 
antipsychotic drugs (e.g., phenothiazine, thioridazine) 
have also been described as DNA-intercalators; in ad-
dition, their efflux pump-inhibitory properties were 
also experimentally verified on many bacterial strains 
(Amaral et al., 2004). The adjuvant properties of non-
steroidal anti-inflammatory drugs (NSAIDs) in bacterial 
infections have been supported in the clinical practice by 
empirical evidence, while laboratory studies have also 
Minimal inhibitory concentrations (µg/mL)
Compounds S. aureus ATCC 25923 S. epidermidis ATCC 12228
MICs of reference antibiotics: Ciprofloxacin: 0.12 µg/mL Gentamicin: 0.12 µg/mL Ciprofloxacin: 0.12 µg/mL Gentamicin: 0.06 µg/mL
Acetaminophen 0.12 0.12 0.12 0.06
Amantadine 0.12 0.12 0.12 0.06
Acyclovir 0.12 0.12 0.12 0.06
Atorvastatin 0.015 0.06 0.0075 0.03
Azelastine 0.06 0.12 0.12 0.06
Celecoxib 0.015 0.12 0.03 0.06
Cetirizine 0.12 0.12 0.12 0.06
Clotrimazole 0.06 0.06 0.06 0.03
Diclofenac-epolamine 0.06 0.12 0.03 0.06
Enalapril-maleate 0.12 0.12 0.12 0.06
Ivermectin 0.03 0.12 0.03 0.06
Lidocaine 0.06 0.06 0.06 0.06
Mebendazole 0.03 0.12 0.12 0.06
Metformin 0.12 0.12 0.12 0.06
Metoprolol-succinate 0.12 0.12 0.12 0.06
Prazozine 0.12 0.12 0.12 0.06
Sitagliptine 0.12 0.12 0.12 0.06
Terbinafine 0.015 0.12 0.03 0.06
Valsartan 0.06 0.06 0.03 0.03
Xylomethazoline 0.12 0.12 0.12 0.06
Results in boldface represent cases when the MICs have decreased due to the effect of the adjuvants.
Table 2 Results of the MIC reduction assays on Gram-positive bacterial strains using ciprofloxacin and gentamicin as reference antibiotics.
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provided results that some NSAIDs (e.g., acetamino-
phen, acetyl-salicylic acid, ibuprofen, indomethacin, 
metamizol-sodium, etoricoxib) and local anesthetics (e.g., 
lidocaine) may have mechanisms enhancing the effects 
of antibiotics in vivo (Al-Bakri et al. 2009; Chan et al. 
2017; D’Angelo et al. 2018; Johnson et al. 2008; Ogundeji 
et al. 2016; Thangamani et al. 2015). These mechanisms 
may include inhibition of biofilm-formation, adherence, 
reduction of motility and the modulating the release of 
antibiotics by leukocytes (Al-Bakri et al. 2009; Chan et al. 
2017; D’Angelo et al. 2018; Johnson et al. 2008; Ogundeji 
et al. 2016; Thangamani et al. 2015). Allopurinol (a gout 
medication) increased the potency of anti-tuberculosis 
medications against Mycobacterium tuberculosis (Naftalin 
et al. 2017). The antibacterial activity of azole antifungals 
and ivermectin against Gram-positive bacteria only was 
previously described (Ghannoum and Rice 1999; Ashraf 
et al. 2018). The exact mechanism of action is not well-
defined, but it is probably associated with affecting the 
binding to the terminal D-alanyl-D-alanine of the penta-
peptide peptidoglycan precursors in the cell wall (Ghan-
noum and Rice 1999; Ashraf et al. 2018). The mechanism 
of statins (including simvastatin and atorvastatin among 
others) regarding their antibacterial potency also needs 
further studies, however, it has been suggested that they 
interfere with the mevalonate pathway, limiting the syn-
thesis of the major lipid constituents of cell membrane 
microdomains (Ko et al. 2017). Apart from drugs, some 
publications also reported on the adjuvant properties of 
vitamins, enhancing the bactericidal activity of antibiot-
ics; these publications highlight the role of high-dose of 
lipid soluble vitamins (ADEK) and Vitamin C (Andrade 
et al. 2014; Kwiencinska-Piróg et al. 2019). 
Conclusions
The aim of our present study was to assess a selection 
of non-antibiotic pharmaceutical compounds – sourced 
from diverse clinical indications and molecular char-
acteristics – as antibiotic adjuvants. Currently, there 
are around 6000-9000 drug compounds marketed for 
human therapeutic purposes; these agents may be con-
sidered as potential combination agents with reference 
antibiotics, to potentiate their antibacterial properties 
in clinical situations. The pharmacokinetic parameters 
and in vivo tolerability of these compounds have already 
been described; thus, these compounds are already one 
Minimal inhibitory concentrations (µg/mL)
Compounds E. coli ATCC 25922 K. pneumoniae ATCC 700603
MICs of reference antibiotics: Ciprofloxacin: 0.004 µg/mL Gentamicin: 0.5 µg/mL Ciprofloxacin: 0.12 µg/mL Gentamicin: 0.05 µg/mL
Acetaminophen 0.004 0.5 0.12 0.5
Amantadine 0.004 0.5 0.12 0.5
Acyclovir 0.004 0.5 0.12 0.5
Atorvastatin 0.004 0.5 0.12 0.5
Azelastine 0.004 0.5 0.12 0.5
Celecoxib 0.001 0.5 0.03 0.5
Cetirizine 0.001 0.25 0.6 0.5
Clotrimazole 0.004 0.5 0.12 0.5
Diclofenac-epolamine 0.002 0.5 0.6 0.5
Enalapril-maleate 0.002 0.5 0.12 0.5
Ivermectin 0.004 0.5 0.12 0.5
Lidocaine 0.001 0.5 0.03 0.5
Mebendazole 0.004 0.5 0.12 0.5
Metformin 0.004 0.5 0.12 0.5
Metoprolol-succinate 0.004 0.5 0.12 0.5
Prazozine 0.004 0.5 0.12 0.5
Sitagliptine 0.004 0.5 0.12 0.5
Terbinafine 0.004 0.5 0.12 0.5
Valsartan 0.001 0.125 0.6 0.5
Xylomethazoline 0.002 0.5 0.12 0.5
Table 3 Results of the MIC reduction assays on Gram-negative bacterial strains using ciprofloxacin and gentamicin as reference antibiotics.
Results in boldface represent cases when the MICs have decreased due to the effect of the adjuvants.
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step closer into their clinical utilization. The highlights 
of the study include the study of twenty pharmaceutical 
compounds that are frequently used by patients. Eight 
tested compounds showed antibacterial activity on the 
tested bacterial strains and several agents presented with 
various degrees of adjuvant (MIC-reducing) properties. 
Further experiments involving the screening of additional 
pharmaceutical compounds for their secondary antibac-
terial and adjuvant properties is definitely warranted. 
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